According to forecasts, the global therapeutic apheresis industry size is expected to be US$ 2,717.9 million in 2023 and US$ 5,264.4 million by 2033, the demand for therapeutic apheresis is estimated to rise at a CAGR of 6.8% during the forecast period.
The rising prevalence of diseases, increased demand for blood components, and the safety that goes along with them are the key components for market growth. Moreover, technological advancements in creating new apheresis techniques and increasing reimbursement policies and funding for apheresis procedures are the market-driving forces.
Also, the market expansion is anticipated to be fueled by the increased incidence of blood-related illnesses, the availability of supportive government initiatives, and reimbursement frameworks. Moreover, it is projected that the demand for apheresis equipment is supported throughout the forecast period by the increased popularity and involvement in blood donation campaigns and camps and the rising number of blood transfusions.
Request A Sample Copy Of This Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-5863
The expansion of the North American therapeutic apheresis industry is anticipated to be constrained by the need for more donor availability and histocompatibility. For instance, barely 3% of Americans give blood, according to a June 2019 article from the American Red Cross.
Key Takeaways
- By 2033, the therapeutic apheresis industry in the United Kingdom is likely to expand, with a CAGR of 4.8%.
- In 2022, the United States developed the therapeutic apheresis business with a share of 28.8%.
- The therapeutic apheresis industry grew considerably to US$ 2,577.9 million in 2022.
- The therapeutic apheresis sector expanded at a CAGR of 4.4% from 2018 to 2022.
- By 2033, China’s therapeutic apheresis industry is projected to develop with a CAGR of 8.3%.
- By 2033, India’s therapeutic apheresis industry is projected to expand with a CAGR of 6.8%.
- Japan’s therapeutic apheresis industry grew significantly, with a 4.2% share in 2022.
- Australia’s therapeutic apheresis industry is likely to expand with a CAGR of 6.1% by 2033.
- Germany’s therapeutic apheresis business grew, with a share of 6.3% in 2022.
- In 2022, based on the technology, centrifugation dominated the market, with a share of 58.3%.
- In 2022, the blood bank segment dominated the market, with a share of 43.5%, based on end users.
Competitors Winning Strategies:
The market has currently demonstrated budding success and is well-established in several locations. As a result of growing government activities, more individuals are becoming aware of the industry under study, fueling its expansion. Strategic partnerships and new product launches by large corporations are also anticipated to fuel market expansion.
Our Analyst Is Available To Help You With Any Inquiries You May Have: https://www.futuremarketinsights.com/ask-question/rep-gb-5863
Recent Developments:
- The TORAYMYXIN medical device was introduced to the European market by Toray Medical Co. Ltd. (Japan) in June 2019.
- Baxter International Inc. (United States) introduced the PrisMax system in the US in July 2019.
- In June 2022, Terumo Blood and Cell Technologies announced that the automated red blood cell exchange procedure performed on the company’s Spectra Optia Apheresis System had been selected by the NHS MedTech Funding Mandate (MTFM) programme in NHS England in the United Kingdom to treat sickle cell disease.
- In July 2022, Eliaz Therapeutics and Terumo Blood and Cell Technologies worked together to create and market a breakthrough therapeutic apheresis therapy for acute renal damage (AKI).
Key Players:
- Asahi Kasei Medical Co.
- Haemonetics Corporation
- Miltenyi Biotec
- Cerus Corporation
- Terumo BCT Inc.
- Fresenius Kabi USA
- Terumo Bct
- B. Braun Melsungen AG
- Nikkiso Co. Ltd.
- Medica S.p.A.
- Baxter Healthcare Corporation
- Kawasumi Laboratories Inc.
- Therakos Incorporation
Elevate Your Brand: Explore the Insights from Our Customization Report: https://www.futuremarketinsights.com/customization-available/rep-gb-5863
Key Segments:
By Procedure Types:
- Therapeutic Plasma Exchange (TPE)
- Red Blood Cell Exchange (RBCX)
- Cellular Depletions
By Technology:
- Centrifugation
- Membrane filtration
By Application:
- Hematology
- Neurology
- Nephrology
- Rheumatology
- Oncology
- Others
By End User:
- Hospitals
- Blood banks
- Specialty clinics
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
